[A17-47] Osimertinib (lung cancer) - Addendum to Commission A17-20

Last updated 19.10.2017

Project no.:

Commission awarded on 12.09.2017 by the Federal Joint Committee (G-BA).

Report type:

Commission completed

Drug Assessment

Application field:


Advanced NSCLC (lung cancer) with T790M mutation after pretreatment with EGFR-TKI

Result of dossier assessment:

Unchanged hint of non-quantifiable, at least considerable added benefit versus cisplatin + pemetrexed


If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Project no. Title Status
A17-20 Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V Commission completed

Federal Joint Committee (G-BA)

2017-10-19 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.